E. Calabrese, V. Calabrese, J. Giordano
Feb 8, 2021
Citations
0
Influential Citations
14
Citations
Journal
Ageing Research Reviews
Abstract
This paper provides evidence to support that riluzole, an FDA-approved treatment for amyotrophic lateral sclerosis (ALS), like many neuroprotective agents, displays and exerts hormetic biphasic dose responses. These findings have important implications for the experimental study and clinical treatment of ALS.